These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25267273)

  • 1. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
    Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
    Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANXA3/JNK Signaling Promotes Self-Renewal and Tumor Growth, and Its Blockade Provides a Therapeutic Target for Hepatocellular Carcinoma.
    Tong M; Fung TM; Luk ST; Ng KY; Lee TK; Lin CH; Yam JW; Chan KW; Ng F; Zheng BJ; Yuan YF; Xie D; Lo CM; Man K; Guan XY; Ma S
    Stem Cell Reports; 2015 Jul; 5(1):45-59. PubMed ID: 26095609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
    Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
    Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells.
    Sun JC; Pan K; Chen MS; Wang QJ; Wang H; Ma HQ; Li YQ; Liang XT; Li JJ; Zhao JJ; Chen YB; Pang XH; Liu WL; Cao Y; Guan XY; Lian QZ; Xia JC
    Cancer Biol Ther; 2010 Aug; 10(4):368-75. PubMed ID: 20581468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
    Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
    Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
    Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
    Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
    Asano T; Hirohashi Y; Torigoe T; Mariya T; Horibe R; Kuroda T; Tabuchi Y; Saijo H; Yasuda K; Mizuuchi M; Takahashi A; Asanuma H; Hasegawa T; Saito T; Sato N
    Oncotarget; 2016 Mar; 7(10):11223-37. PubMed ID: 26849232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
    Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
    Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
    Liu YM; Li XF; Liu H; Wu XL
    Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma.
    Pan QZ; Pan K; Weng DS; Zhao JJ; Zhang XF; Wang DD; Lv L; Jiang SS; Zheng HX; Xia JC
    Mol Carcinog; 2015 Aug; 54(8):598-607. PubMed ID: 24375474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma.
    Ma XL; Jiang M; Zhao Y; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Cao Y; Pan BS; Zhou J; Fan J; Yang XR; Guo W
    Ann Surg Oncol; 2018 Jun; 25(6):1686-1694. PubMed ID: 29626309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
    Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
    Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133⁺ cancer stem-like cells in hepatocellular carcinoma.
    Yan M; Li H; Zhu M; Zhao F; Zhang L; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    PLoS One; 2013; 8(4):e61056. PubMed ID: 23593389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
    Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
    Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
    Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
    PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy.
    Li J; Chen JN; Zeng TT; He F; Chen SP; Ma S; Bi J; Zhu XF; Guan XY
    BMC Cancer; 2016 Jan; 16():15. PubMed ID: 26758620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
    Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
    Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
    Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.